Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863377 | 1.00 | NPSR1 (0.33) | NPSR1MAPTKEAP1NFE2L2HCAR2 | |
| SCHEMBL2547049 | 0.83 | — | — | |
| SCHEMBL4869779 | 0.81 | POLB (0.32) | NPSR1MAPT | |
| SCHEMBL4869772 | 0.81 | POLB (0.32) | NPSR1MAPT | |
| SCHEMBL4864227 | 0.79 | NPSR1 (0.47) | NPSR1MAPTLMNA | |
| SCHEMBL1971946 | 0.79 | NPSR1 (0.42) | NPSR1MAPTLMNA | |
| SCHEMBL4872719 | 0.78 | NPSR1 (0.45) | NPSR1MAPTLMNA | |
| SCHEMBL2305290 | 0.78 | NPSR1 (0.45) | NPSR1MAPTLMNA | |
| SCHEMBL4870473 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL6234603 | 0.77 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | NPSR1 3037/4885MAPT 3716/4885KEAP1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.